1. Generics Bulletin
  2. >>Business

ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio

The Move Reflects ANI’s Ambition To Increase Foothold In Rare Disease

 
• By Adam Zamecnik

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

Illustrative image of a deal
• Source: Shutterstock

ANI Pharmaceuticals will acquire Alimera Sciences in a deal that values the firm at $381m in upfront consideration, after signing a definitive agreement in a move that is seen as an effort to gain a foothold in ophthalmology and expand its rare diseases business.

ANI will pay $5.50 per share in cash at closing, with one non-tradable contingent value right representing the right to receive up to $0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.